# YN001 in Healthy Subjects and Patients With Coronary Atherosclerosis

Study · id `cardio:ct-nct06048588` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06048588](<https://clinicaltrials.gov/study/NCT06048588>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT06048588

Browse, organ or system: Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 1/2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 144 participants.

## Technical summary

Registry record NCT06048588. Randomized; triple masking; primary purpose treatment. Start 2023-10-08 (actual); primary completion 2025-04-27 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 1/2
- Enrolled: 144 participants (enrolled count; ClinicalTrials.gov record NCT06048588, source copy `cardio:ctgov-nct06048588-2026-09-22`, retrieved 2026-10-31)
- Started: 2023-10-08 (actual) (ClinicalTrials.gov record NCT06048588, source copy `cardio:ctgov-nct06048588-2026-09-22`, retrieved 2026-10-31)
- Primary completion: 2025-04-27 (actual) (ClinicalTrials.gov record NCT06048588, source copy `cardio:ctgov-nct06048588-2026-09-22`, retrieved 2026-10-31)
- Completion: 2025-04-27 (actual) (ClinicalTrials.gov record NCT06048588, source copy `cardio:ctgov-nct06048588-2026-09-22`, retrieved 2026-10-31)
- Countries: China (ClinicalTrials.gov record NCT06048588, source copy `cardio:ctgov-nct06048588-2026-09-22`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06048588-2026-09-22`, retrieved 2026-10-31)

## The registry's words

- Brief title: YN001 in Healthy Subjects and Patients With Coronary Atherosclerosis
- Condition: Atherosclerotic Cardiovascular Disease
- Intervention (Drug): YN001
- Intervention (Drug): Placebo for YN001
- Intervention (Drug): rosuvastatin calcium tablets
- Lead sponsor: Beijing Inno Medicine Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Atherosclerosis (`cardio:atherosclerosis`)

## Provenance

Content hash: ad7543c53dc4ac4fac60b00a1edaf51d453c27d92e137fd0a0b71e4358ce09ce
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
